Dapolsertib

Dapolsertib
Clinical data
Other names	MEN1703, SEL24-B489
Identifiers
	IUPAC name 5,6-dibromo-4-nitro-2-piperidin-4-yl-1-propan-2-ylbenzimidazole;
CAS Number	1616359-00-2;
PubChem CID	76286825;
IUPHAR/BPS	13204;
ChemSpider	81367232;
UNII	9M7X64VTLI;
ChEMBL	ChEMBL4467168;
Chemical and physical data
Formula	C15H18Br2N4O2
Molar mass	446.143 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)N1C2=CC(=C(C(=C2N=C1C3CCNCC3)[N+](=O)[O-])Br)Br;
	InChI InChI=InChI=1S/C15H18Br2N4O2/c1-8(2)20-11-7-10(16)12(17)14(21(22)23)13(11)19-15(20)9-3-5-18-6-4-9/h7-9,18H,3-6H2,1-2H3; Key:UOUBCIJIWDLRGM-UHFFFAOYSA-N;

Dapolsertib is an investigational new drug that is being evaluated for the treatment of cancer. It is dual inhibitor of PIM family of serine/threonine protein kinases and mutant forms of FMS-related tyrosine kinase 3 (FLT3) that is being developed by Ryvu Therapeutics SA.^[1]

References

↑ Wu M, Li C, Zhu X (December 2018). "FLT3 inhibitors in acute myeloid leukemia". Journal of Hematology & Oncology. 11 (1) 133. doi:10.1186/s13045-018-0675-4. PMC 6280371. PMID 30514344.

[pmid30514344-1] Wu M, Li C, Zhu X (December 2018). "FLT3 inhibitors in acute myeloid leukemia". Journal of Hematology & Oncology. 11 (1) 133. doi:10.1186/s13045-018-0675-4. PMC 6280371. PMID 30514344.

[1]